Fig. 4
From: Repurposed drugs in combinations exert additive anti-chikungunya virus activity: an in-vitro study
(A) Western blot images were shown, demonstrating variations in viral protein expression in cultures treated with individual drugs or their combinations. The blots for individual drugs included (a) envelope protein expression and: Lane-1: 2FA 100µM, Lane-2: EM 200µM, Lane-3: EN 1.56µM, and Lane-4: M 200µM. The blots for combined drugs (c) Lane-1: 2FA + EM 100µM + 200µM; Lane-2: 2FA + EM 50µM + 100µM; Lane-3: 2FA + EN 100µM + 1.56µM; Lane-4: 2FA + EN 50µM + 0.78µM; Lane-5: 2FA + M 100µM + 200µM; Lane-6: 2FA + M 50µM + 100µM. (b &d) β-actin expression. VC: Virus control CC: Cell control PM: Protein marker. (B) ImageJ software was used to analyze the band density intensities of the envelope antigens (mean ± SE, n = 3 replicates). Lane-1, 3, and 5 exhibited a significant reduction in envelope antigens compared to VC. Statistical analysis was performed using one-way ANOVA with multiple comparisons against the viral control, indicated by *** p < 0.0004. The combination drugs (d) Shows RT-PCR results, a higher percentage of viral reduction compared to individual drugs. The graph compares the different concentrations combination drugs with the viral control. All values are expressed as mean ± SE of three individual experiments. Statistical analysis was performed using one-way ANOVA multiple comparisons with viral control and indicated by *** p < 0.0004